Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780055 | 0.82 | PDE10A (0.50) | PDE10ALTB4RCYP1A2 | |
| SCHEMBL8029278 | 0.72 | GRM5 (0.54) | PDE10ACYSLTR1CYSLTR2GPBAR1ALOX5 | |
| SCHEMBL9335591 | 0.72 | LTB4R (0.58) | PDE10ALTB4RCYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL10512475 | 0.71 | PDE10A (0.77) | PDE10ACYSLTR1CYSLTR2GPBAR1CYP1A2 | |
| SCHEMBL4780912 | 0.69 | PDE10A (0.47) | PDE10A | |
| SCHEMBL14212421 | 0.68 | ITGB2 (0.39) | — | |
| SCHEMBL7801525 | 0.68 | MAPT (0.56) | PDE10ACYSLTR1CYSLTR2GPBAR1ALOX5 | |
| SCHEMBL27816005 | 0.67 | CYSLTR1 (0.64) | PDE10ACYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL8034954 | 0.67 | ALOX5 (0.48) | PDE10ALTB4RCYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL8462779 | 0.67 | LTB4R (0.59) | PDE10ALTB4RCYSLTR1CYSLTR2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103161-B1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-4103161-A1 | COMPOSITIONS AND USES THEREOF | BenevolentAI Cambridge Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
| CN-115484938-A | Composition and use thereof | 博善人工智能剑桥有限公司 | 2022-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | PDE2A, PDE3A, PDE3B | PDE10A 5/4885LTB4R 254/4885CYSLTR1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.